Literature DB >> 20386769

Long-term influence of mild or moderate ischemic mitral regurgitation after off-pump coronary artery bypass surgery.

Jong-Myeon Hong1, Raymond Cartier, Michel Pellerin, Philippe Demers, Denis Bouchard, P Couture.   

Abstract

BACKGROUND: The issue of mild to moderate ischemic mitral regurgitation (IMR) is controversial after conventional surgery, and has not been specifically studied after off-pump coronary artery bypass graft (OPCAB) surgery.
OBJECTIVE: To review the influence of mild or moderate IMR on longterm survival and recurrent cardiac events after OPCAB surgery.
METHODS: A total of 1000 consecutive and systematic OPCAB patients who underwent operations between September 1996 and March 2004 were prospectively followed. Sixty-seven patients (6.7%) had mild to moderate IMR at the time of surgery. Operative mortality, actuarial survival and major adverse cardiac event-free survival were studied to assess the effect of IMR.
RESULTS: The mean (+/- SD) follow-up period was 66+/-22 months and was completed in 97% of the cohort. IMR patients were older (P<0.001), and had lower ejection fractions (P<0.001) and more comorbidities. More female patients presented with IMR (P=0.002). Operative mortality (P=0.25) and prevalence of perioperative myocardial infarction (P=0.25) were comparable for both groups. Eight-year survival was decreased in IMR patients (P<0.001), but after adjusting for risk factors in the Cox regression model, mild to moderate IMR was not found to be a significant risk factor of long-term mortality (P=0.42). Major adverse cardiac event-free survival at eight years was significantly lower in IMR patients (P<0.001) and, more specifically, in patients with 2+ IMR. After adjusting for risk factors, IMR remained a significant cause of poor outcome (hazard ratio 2.09), especially for recurrent congestive heart failure and myocardial infarction.
CONCLUSIONS: OPCAB patients with preoperative mild or moderate IMR had a higher prevalence of preoperative risk factors than those without IMR. They had comparable perioperative mortality and morbidity but, over the long term, were found to be at risk for recurrent cardiac events.

Entities:  

Mesh:

Year:  2010        PMID: 20386769      PMCID: PMC2886544          DOI: 10.1016/s0828-282x(10)70368-8

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  24 in total

1.  Coronary angioplasty for acute mitral regurgitation due to myocardial infarction. A nonsurgical treatment preserving mitral valve integrity.

Authors:  R R Heuser; G L Maddoux; J E Goss; B W Ramo; G L Raff; N Shadoff
Journal:  Ann Intern Med       Date:  1987-12       Impact factor: 25.391

2.  Initial report of off-pump coronary artery bypass surgery as sole therapy for moderate ischemic mitral regurgitation: operative and intermediate-term outcome.

Authors:  Kevin M Harris; Avinash Reddy; Dorothee Aepplii; Betsy Wilson; Robert W Emery
Journal:  Heart Surg Forum       Date:  2005       Impact factor: 0.676

3.  Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction.

Authors:  Audrey H Wu; Keith D Aaronson; Steven F Bolling; Francis D Pagani; Kathy Welch; Todd M Koelling
Journal:  J Am Coll Cardiol       Date:  2005-02-01       Impact factor: 24.094

4.  Coronary revascularization without cardiopulmonary bypass versus the conventional approach in high-risk patients.

Authors:  Sotiris C Stamou; Kathleen A Jablonski; Peter C Hill; Ammar S Bafi; Steven W Boyce; Paul J Corso
Journal:  Ann Thorac Surg       Date:  2005-02       Impact factor: 4.330

5.  Importance of moderate ischemic mitral regurgitation.

Authors:  B-Khanh Lam; A Marc Gillinov; Eugene H Blackstone; Jeevanantham Rajeswaran; Bertram Yuh; Sunil K Bhudia; Patrick M McCarthy; Delos M Cosgrove
Journal:  Ann Thorac Surg       Date:  2005-02       Impact factor: 4.330

6.  Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial.

Authors:  M St John Sutton; M A Pfeffer; L Moye; T Plappert; J L Rouleau; G Lamas; J Rouleau; J O Parker; M O Arnold; B Sussex; E Braunwald
Journal:  Circulation       Date:  1997-11-18       Impact factor: 29.690

7.  Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators.

Authors:  G A Lamas; G F Mitchell; G C Flaker; S C Smith; B J Gersh; L Basta; L Moyé; E Braunwald; M A Pfeffer
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

8.  Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Authors:  Gregory G Pellizzon; Cindy L Grines; David A Cox; Thomas Stuckey; James E Tcheng; Eulogio Garcia; Giulio Guagliumi; Mark Turco; Alexandra J Lansky; John J Griffin; David J Cohen; Eve Aymong; Roxana Mehran; William W O'Neill; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

9.  Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data.

Authors: 
Journal:  Circulation       Date:  1983-11       Impact factor: 29.690

10.  Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

Authors:  M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.